financetom
Business
financetom
/
Business
/
CyberArk Software's Identity Security Remains an Enterprise Focus Area, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CyberArk Software's Identity Security Remains an Enterprise Focus Area, UBS Says
Apr 24, 2024 1:43 PM

04:15 PM EDT, 04/24/2024 (MT Newswires) -- CyberArk Software's ( CYBR ) enterprise focus on identity security remains strong, with positive feedback from partners regarding privileged access management, UBS Securities said in a report emailed Wednesday.

The company's shares are currently trading at levels seen before in Q4, and there's optimism leading up to the upcoming May 2 earnings report, UBS said, adding that "we see platform opps in Access and DevOps/Cloud inflecting higher this quarter."

Opportunities in Identity and Access Management and significant deal activity in Q1, support CyberArk's competitive advantage. The recent acquisition of HashiCorp is viewed positively, potentially benefiting CyberArk in the DevOps access market, especially with the momentum in Secure Cloud Access, UBS said.

Q1 expectations seem reasonable, with analysts forecasting $34 million of Non-GAAP Net Annual Recurring Revenue, flat year-over-year, and a 5% Operating margins, the report said.

"Despite a very strong [2023] and a relatively demanding valuation, we continue to think [CyberArk] shares look attractive here. Critically, identity security remains a significant focus area, and we think [CyberArk] has a unique opportunity to capitalize on industry disruption as it expands its own platform of product offerings," UBS said.

UBS has a buy rating on CyberArk with a 12-month price target of $310.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Eli Lilly's drug for eczema
US FDA approves Eli Lilly's drug for eczema
Sep 13, 2024
Sept 13 (Reuters) - Eli Lilly ( LLY ) said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, branded Ebglyss, will be available in the next few weeks, the company said. The FDA's approval was based on three studies involving over 1,000 patients with...
Rbc Bearings Insider Sold Shares Worth $14,477,592, According to a Recent SEC Filing
Rbc Bearings Insider Sold Shares Worth $14,477,592, According to a Recent SEC Filing
Sep 13, 2024
04:28 PM EDT, 09/13/2024 (MT Newswires) -- Michael J Hartnett, Director, President and CEO, on September 11, 2024, sold 50,860 shares in Rbc Bearings ( RBC ) for $14,477,592. Following the Form 4 filing with the SEC, Hartnett has control over a total of 312,954 shares of the company, with 312,954 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1324948/000159396824001198/xslF345X05/primary_01.xml Price: 284.10, Change:...
--TPG RE Finance Trust Keeps Quarterly Dividend at $0.24 a Share, Payable Oct. 25 to Holders of Record Sept. 27
--TPG RE Finance Trust Keeps Quarterly Dividend at $0.24 a Share, Payable Oct. 25 to Holders of Record Sept. 27
Sep 13, 2024
04:28 PM EDT, 09/13/2024 (MT Newswires) -- Price: 9.28, Change: +0.26, Percent Change: +2.90 ...
GR Silver Mining Upsizes Private Placement Financing to $2 Million
GR Silver Mining Upsizes Private Placement Financing to $2 Million
Sep 13, 2024
04:27 PM EDT, 09/13/2024 (MT Newswires) -- GR Silver Mining ( GRSLF ) said Friday afternoon that it is expanding its private placement offer due to higher-than-expected interest. The company will now offer up to 12.5-million units priced at $0.16 each,, aiming to raise up to $2 million. It had previously planned to raise $1.76 million by selling up to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved